文献速递消化系统肿瘤

奥沙利铂联合氟尿嘧啶动脉化疗对比索拉非尼治疗晚期肝细胞癌:生物分子探索性、随机、III期试验(FOHAIC-1)

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
PubMed 文献 · J Clin Oncol · 2021-12-14

这项开放标签III期试验将262例未经系统治疗的晚期肝细胞癌患者随机分配接受HAIC-FO或索拉非尼,主要终点为意向治疗人群的总生存期。HAIC-FO组中位OS为13.9个月,索拉非尼组为8.2个月(HR 0.408,95%CI 0.301-0.552,P<.001)。HAIC-FO在高危亚组中也显示更长的OS,并开发了15基因预测模型识别应答者。

要点

  • HAIC-FO较索拉非尼显著延长晚期肝细胞癌患者的中位OS(13.9 vs 8.2个月,HR 0.408)。
  • HAIC-FO组16例(12.3%)实现肿瘤降期,其中15例接受治愈性手术或消融,中位OS达20.8个月。
  • 15基因预测模型可识别83%对HAIC-FO应答的患者,应答者OS长于无应答者(19.3 vs 10.6个月,HR 0.323)。

核心结论

  • 在晚期肝细胞癌患者中,HAIC-FO较索拉非尼取得更好的生存结局,即使合并高肝内肿瘤负荷。

研究设计与样本

  • 开放标签、随机、III期试验,于2017年5月至2020年5月入组262例未经系统治疗的晚期肝细胞癌患者,按1:1随机分配接受HAIC-FO或索拉非尼,主要终点为意向治疗人群的总生存期,并开发基于基因组测序的探索性疗效预测模型。

主要发现

  • 中位肿瘤大小为11.2 cm(四分位距8.5-13.7 cm),大血管侵犯占65.6%,肿瘤体积超过肝脏50%和/或Vp-4门静脉癌栓的患者占49.2%。
  • 数据截止2020年10月31日,HAIC-FO组中位OS为13.9个月,索拉非尼组为8.2个月(HR 0.408;95%CI 0.301-0.552;P<.001)。
  • 130例HAIC-FO患者中16例(12.3%)发生肿瘤降期,其中15例接受治愈性手术或消融,最终中位OS为20.8个月,1年OS率为93.8%。
  • 高危亚组中HAIC-FO的OS显著长于索拉非尼(10.8个月 vs 5.7个月;HR 0.343;95%CI 0.219-0.538;P<.001)。
  • 新开发的15突变基因预测模型识别了83%对HAIC-FO应答的患者,HAIC-FO应答者OS长于无应答者(19.3个月 vs 10.6个月;HR 0.323;95%CI 0.186-0.560;P=.002)。

关键数值与推荐

  • HAIC-FO方案为介入性肝动脉灌注化疗,输注氟尿嘧啶、亚叶酸钙和奥沙利铂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC). METHODS: In this open-label, phase III trial, patients with advanced HCC, previously untreated with systemic therapy, were randomly assigned in a 1:1 ratio to receive HAIC-FO or sorafenib. The primary end point was overall survival (OS) in the intention-to-treat population. An exploratory model for predicting the efficacy of HAIC-FO on the basis of genomic sequencing was developed. RESULTS: Between May 2017 and May 2020, 262 patients were randomly assigned. The median tumor size was 11.2 cm (interquartile range, 8.5-13.7 cm). Macrovascular invasion was present in 65.6%, and the percentage of patients with > 50% tumor volume involvement of the liver and/or Vp-4 portal vein tumor thrombosis was 49.2%. At data cutoff (October 31, 2020), median OS was 13.9 months for HAIC-FO and 8.2 for sorafenib (hazard ratio [HR] 0.408; 95% CI, 0.301 to 0.552; P < .001). Tumor downstaging occurred in 16 (12.3% of 130) patients receiving HAIC-FO, including 15 receiving curative surgery or ablation, and finally achieving a median OS of 20.8 months, with a 1-year OS rate of 93.8%. In high-risk subpopulations, OS was significantly longer with HAIC-FO than with sorafenib (10.8 months v 5.7 months; HR 0.343; 95% CI, 0.219 to 0.538; P < .001). A newly developed 15-mutant-gene prediction model identified 83% of patients with response to HAIC-FO. HAIC-FO responders had longer OS than HAIC-FO nonresponders (19.3 months v 10.6 months; HR 0.323; 95% CI, 0.186 to 0.560; P = .002). CONCLUSION: HAIC-FO achieved better survival outcomes than sorafenib in advanced HCC, even in association with a high intrahepatic disease burden.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lyu N, Wang X, Li JB, et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2021. PMID: 34905388. doi:10.1200/JCO.21.01963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。